More importantly, our data showed for the first time that OS and RFS were significantly shorter in AML patients with DNMT3A mutations combined with CD7 expression, whereas DNMT3A mutations or CD7-positive expression alone had no significant effect on prognosis. This evidence concerns the gene CD7 and acute myeloid leukemia.